Newsfeed : Successful HIV Vaccine Trial Poses New Questions for Researchers

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Newsfeed » September 2009

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ


More News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

September 25, 2009

Successful HIV Vaccine Trial Poses New Questions for Researchers

While a successful trial of the RV 144 HIV vaccine is a major step forward in HIV/AIDS research, experts say that the vaccine’s efficacy provides few answers but raises many questions, aidsmap.com reports. In a Thailand-based trial—the largest ever staged for an HIV vaccine—RV 144 reduced the risk of HIV infection by more than 30 percent in participants.

“This trial poses fundamental ‘black box’ questions,” said Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), which funded the trial alongside the Thai Ministry of Public Health, the United States Army and patent-holders to the two parts of the vaccine, Sanofi-Pasteur and Global Solutions for Infectious Diseases. 

He continued, “What are the correlates of HIV immunity? Has this trial overturned our understanding of what might constitute a protective response to HIV? Can we improve on this efficacy? And does this result mean we should refocus more on clinical research than basic science? Not at all. NIAID’s commitment to keeping an appropriate balance between basic science and vaccinology versus empirical clinical trials has not changed.”

According to the article, some scientists viewed the RV 144 trial as a waste of money given its $105 million price tag.

“We did hesitate to continue the trial because of the criticism from the scientific point of view,” said principal investigator Supachai Rerks-Ngarm, MD. “But in view of the need for an HIV vaccine, and in consultation with many international experts, we decided to move forward. That determination turned out to be very significant.”

Search: vaccine, RV 144, Thailand, Fauci, NIAID, U.S. Army, Sanofi-Pasteur, Global Solutions for Infectious Diseases


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (2 total)

 
[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.